← Every applicant
Novartis FDA Approvals
12 new drug approvals and 0 device clearances on file. This applicant is not matched to a listed company.
Newest first
A new drug approval is an original application; a 510(k) is a device shown equivalent to one already sold.
| Product |
|---|
| RHAPSIDONew drugSep 30, 2025TABLET, ORAL |
| VANRAFIANew drugApr 2, 2025TABLET, ORAL |
| VIJOICENew drugApr 24, 2024GRANULE, ORAL |
| ENTRESTO SPRINKLENew drugApr 12, 2024CAPSULE, PELLETS, ORAL |
| FABHALTANew drugDec 5, 2023CAPSULE, ORAL |
| TAFINLARNew drugMar 16, 2023CAPSULE, ORAL |
| MEKINISTNew drugMar 16, 2023SOLUTION, ORAL |
| VIJOICENew drugApr 5, 2022TABLET, ORAL |
| PLUVICTONew drugMar 23, 2022SOLUTION, INTRAVENOUS |
| LOCAMETZNew drugMar 23, 2022POWDER, INTRAVENOUS |
| LEQVIONew drugDec 22, 2021SOLUTION, SUBCUTANEOUS |
| SCEMBLIXNew drugOct 29, 2021TABLET, ORAL |